Biotech News

Number of shares and voting rights of Innate Pharma as of April 16, 2026

Innate Pharma (IPHA)Innate Pharma2026-05-11 08:09 ESTCompany update

Nouveau nombre d’actions et de droits de vote d’innate Pharma au 16 avril 2026

mar, 05/12/2026 - 07:00

Press release in English 126.91 Ko Communiqué de presse en français 107.71 Ko

helene

lun, 05/11/2026 - 10:41

Innate Pharma

Innate Immunity Oncology Company Innate Pharma develops antibodies and antibody-drug conjugates that engage innate and adaptive immunity against cancer. Lacutamab Lacutamab targets KIR3DL2 and is being developed for cutaneous T-cell lymphoma. ADC and Partnered Pipeline IPH4502 is a Nectin-4 ADC, while partnered programs include...

Recent company news

IPHAInnate Pharma2026-08-14 08:26 EST

Innate Pharma to advance Lacutamab towards phase 3 following partnership with Sobi and appoints new chief medical officer

IPHAInnate Pharma2026-08-09 20:37 EST

Innate Pharma enters strategic partnership with Sobi to license lacutamab in T-cell lymphoma

Stock data

Close: 2.26 USD
Market cap: 170.9M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States

Number of shares and voting rights of Innate Pharma as of April 16, 2026

Related news

Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)

Innate Pharma announces conference call and webcast